行情

ARQL

ARQL

ArQule
NASDAQ

实时行情|Nasdaq Last Sale

8.46
-0.12
-1.40%
已收盘, 16:37 10/14 EDT
开盘
8.55
昨收
8.58
最高
8.58
最低
8.30
成交量
110.45万
成交额
--
52周最高
12.22
52周最低
2.230
市值
10.17亿
市盈率(TTM)
-27.5570
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

ARQL 新闻

  • 加州州长要求太平洋瓦电对上周大面积停电负责
  • 新浪美股.2小时前
  • 安永:中国对外直接投资跻身全球第一梯队
  • 中国新闻网.2小时前
  • 毕马威全球颠覆者报告:阿里巴巴等六家中国公司上榜
  • 新浪财经综合.3小时前
  • 数据:伦交所环球板交易工具(CDI)
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
+0.42%
制药与医学研究
+0.09%

热门股票

名称
价格
涨跌幅

ARQL 简况

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.
展开

Webull提供ArQule, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。